These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

156 related articles for article (PubMed ID: 15793183)

  • 1. Rosiglitazone improves postprandial triglyceride and free fatty acid metabolism in type 2 diabetes.
    van Wijk JP; de Koning EJ; Castro Cabezas M; Rabelink TJ
    Diabetes Care; 2005 Apr; 28(4):844-9. PubMed ID: 15793183
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes.
    Tan GD; Fielding BA; Currie JM; Humphreys SM; Désage M; Frayn KN; Laville M; Vidal H; Karpe F
    Diabetologia; 2005 Jan; 48(1):83-95. PubMed ID: 15619071
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of rosiglitazone on postprandial leukocytes and cytokines in type 2 diabetes.
    van Wijk JP; Cabezas MC; Coll B; Joven J; Rabelink TJ; de Koning EJ
    Atherosclerosis; 2006 May; 186(1):152-9. PubMed ID: 16137694
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Glibenclamide improves postprandial hypertriglyceridaemia in type 2 diabetic patients by reducing chylomicrons but not the very low-density lipoprotein subfraction levels.
    Skrapari I; Perrea D; Ioannidis I; Karabina SA; Elisaf M; Tselepis AD; Karagiannacos P; Katsilambros N
    Diabet Med; 2001 Oct; 18(10):781-5. PubMed ID: 11678967
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Impact of metformin versus the prandial insulin secretagogue, repaglinide, on fasting and postprandial glucose and lipid responses in non-obese patients with type 2 diabetes.
    Lund SS; Tarnow L; Frandsen M; Smidt UM; Pedersen O; Parving HH; Vaag AA
    Eur J Endocrinol; 2008 Jan; 158(1):35-46. PubMed ID: 18166815
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Differential effect of pioglitazone (PGZ) and rosiglitazone (RGZ) on postprandial glucose and lipid metabolism in patients with type 2 diabetes mellitus: a prospective, randomized crossover study.
    Chappuis B; Braun M; Stettler C; Allemann S; Diem P; Lumb PJ; Wierzbicki AS; James R; Christ ER
    Diabetes Metab Res Rev; 2007 Jul; 23(5):392-9. PubMed ID: 17211855
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Abrogation of postprandial triglyceridemia with dual PPAR α/γ agonist in type 2 diabetes mellitus: a randomized, placebo-controlled study.
    Rastogi A; Dunbar RL; Thacker HP; Bhatt J; Parmar K; Parmar DV
    Acta Diabetol; 2020 Jul; 57(7):809-818. PubMed ID: 32030508
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Acute effect of orlistat on post-prandial lipaemia and free fatty acids in overweight patients with Type 2 diabetes mellitus.
    Tan KC; Tso AW; Tam SC; Pang RW; Lam KS
    Diabet Med; 2002 Nov; 19(11):944-8. PubMed ID: 12421432
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Rosiglitazone modulates fasting and post-prandial paraoxonase 1 activity in type 2 diabetic patients.
    van Wijk J; Coll B; Cabezas MC; Koning E; Camps J; Mackness B; Joven J
    Clin Exp Pharmacol Physiol; 2006 Dec; 33(12):1134-7. PubMed ID: 17184491
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Liraglutide suppresses postprandial triglyceride and apolipoprotein B48 elevations after a fat-rich meal in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, cross-over trial.
    Hermansen K; Bækdal TA; Düring M; Pietraszek A; Mortensen LS; Jørgensen H; Flint A
    Diabetes Obes Metab; 2013 Nov; 15(11):1040-8. PubMed ID: 23683069
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Ezetimibe beneficially influences fasting and postprandial triglyceride-rich lipoproteins in type 2 diabetes.
    Bozzetto L; Annuzzi G; Corte GD; Patti L; Cipriano P; Mangione A; Riccardi G; Rivellese AA
    Atherosclerosis; 2011 Jul; 217(1):142-8. PubMed ID: 21481394
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decrease in circulating fibroblast growth factor 21 after an oral fat load is related to postprandial triglyceride-rich lipoproteins and liver fat.
    Matikainen N; Taskinen MR; Stennabb S; Lundbom N; Hakkarainen A; Vaaralahti K; Raivio T
    Eur J Endocrinol; 2012 Mar; 166(3):487-92. PubMed ID: 22190000
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of simvastatin on fasting and postprandial triglyceride-rich lipoproteins in patients with type I diabetes mellitus.
    Noutsou M; Georgopoulos A
    J Diabetes Complications; 1999; 13(2):98-104. PubMed ID: 10432174
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The effects of medications used for the management of diabetes and obesity on postprandial lipid metabolism.
    Eleftheriadou I; Grigoropoulou P; Katsilambros N; Tentolouris N
    Curr Diabetes Rev; 2008 Nov; 4(4):340-56. PubMed ID: 18991602
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Vildagliptin therapy reduces postprandial intestinal triglyceride-rich lipoprotein particles in patients with type 2 diabetes.
    Matikainen N; Mänttäri S; Schweizer A; Ulvestad A; Mills D; Dunning BE; Foley JE; Taskinen MR
    Diabetologia; 2006 Sep; 49(9):2049-57. PubMed ID: 16816950
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The effect of aggressive versus standard lipid lowering by atorvastatin on diabetic dyslipidemia: the DALI study: a double-blind, randomized, placebo-controlled trial in patients with type 2 diabetes and diabetic dyslipidemia.
    Diabetes Atorvastin Lipid Intervention (DALI) Study Group
    Diabetes Care; 2001 Aug; 24(8):1335-41. PubMed ID: 11473066
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A comparison of lipid and glycemic effects of pioglitazone and rosiglitazone in patients with type 2 diabetes and dyslipidemia.
    Goldberg RB; Kendall DM; Deeg MA; Buse JB; Zagar AJ; Pinaire JA; Tan MH; Khan MA; Perez AT; Jacober SJ;
    Diabetes Care; 2005 Jul; 28(7):1547-54. PubMed ID: 15983299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparative effects of rosiglitazone and pioglitazone on fasting and postprandial low-density lipoprotein size and subclasses in patients with Type 2 diabetes.
    Berneis K; Rizzo M; Stettler C; Chappuis B; Braun M; Diem P; Christ ER
    Expert Opin Pharmacother; 2008 Feb; 9(3):343-9. PubMed ID: 18220486
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Exenatide suppresses postprandial elevations in lipids and lipoproteins in individuals with impaired glucose tolerance and recent onset type 2 diabetes mellitus.
    Schwartz EA; Koska J; Mullin MP; Syoufi I; Schwenke DC; Reaven PD
    Atherosclerosis; 2010 Sep; 212(1):217-22. PubMed ID: 20557887
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Postprandial lipid metabolism and beta-cell function in non-insulin-dependent (type 2) diabetes mellitus after a mixed meal with a high fat content.
    Cooper MB; Tan KC; Hales CN; Betteridge DJ
    Diabet Med; 1996 Sep; 13(9):816-27. PubMed ID: 8891457
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.